Kirkstall has developed Quasi Vivo™, an advanced interconnected cell culture flow system, engineered to provide in vivo-like conditions for cell growth. Its patented technology is used by researchers in academia and drug development and provides a way to model the behaviour of multiple human organs interconnected by a system that mimics the flow of blood in the body. It can significantly increase the physiological relevance of research, helping users generate more accurate models and greatly improve confidence in the validity of their results.
The company runs an annual conference called Advances in Cell and Tissue Culture and recently launched its new cell culture product QV1200. Braveheart owns 86% of the issued share capital in Kirkstall and also provides strategic management resource to the company.
Find out more about Kirkstall Limited